Nektar Therapeutics (NKTR) on Monday reported positive results from a 16-week treatment extension in its Phase 2b REZOLVE-AA study of rezpegaldesleukin in patients with severe-to-very-severe Alopecia Areata. The company's shares rose more than 17% in pre-market trading.
In the REZOLVE-AA study, during the initial 36-week induction phase, participants were randomized to receive either two dose levels of rezpegaldesleukin or placebo. Patients who completed the induction phase and had a Severity of Alopecia Tool (SALT) score above 20 at week 36, along with evidence of hair regrowth, were eligible to continue treatment at their assigned dose in a 16-week extension period through week 52.
The study showed continued improvement in hair regrowth through week 52. Between weeks 36 and 52, 29% of patients on the low dose and 31% on the high dose achieved a SALT score of 20 or below, compared with none in the placebo group. A SALT score less than or equal to 20 indicates at least 80% scalp hair coverage.
Nektar said the treatment continued to demonstrate a favorable safety and tolerability profile over 52 weeks, consistent with earlier data.
The company added that the results support advancing rezpegaldesleukin into late-stage development for alopecia areata.
Nektar stock had closed at $84.86 on Friday, up 1.04%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.